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Prostate cancer is the second leading cause of death in males in the
United States and is the most frequently diagnosed malignancy in
men (Rhim, 2000). Early diagnosis of prostate cancer contributes
in improving these detrimental statistics. Prostate cancer screening
has provided a method for early prostate cancer detection and
administration of curative treatments. Since screening appears to
save lives, there is now a need for developing more biomarkers to
improve efficiency (McDavid et al, 2000; Moran et al, 2000; Webb
and Holmes, 2000). Prostate-specific antigen (PSA) analysis is
widely used for prostate cancer monitoring, as well as for early
detection (Oesterling, 1991; McCormack et al, 1995). PSA, which
has prostate-specific expression, has been suggested to be impli-
cated in the initiation and progression of prostate cancer
(Diamandis, 2000). PSA levels in serum are frequently raised in
benign prostatic hyperplasia (BPH), which is a major limitation.
Development of a variety of techniques, which include age-
specific reference ranges, PSA density, PSA velocity and
percentage of free PSA have improved the clinical value of PSA
(Oesterling, 1991; McCormack et al, 1995). 
Many recent studies aim at identifying new genes that might
have the potential to serve as diagnostic and/or prognostic markers
for cancer. Human glandular kallikrein 2 is a serine protease
produced by the prostate which is now used as an additional
biomarker for the diagnosis and management of prostate 
cancer (Rittenhouse et al, 1998; Magklara et al, 1999; Heese et al,
2000). 
PSA and hK2 were thought to be strictly expressed in the
prostate, however, new studies have indicated that both kallikreins
are expressed in diverse tissues and can be easily detected in many
fluids (Black and Diamandis, 2000; Diamandis, 2000). PSA is
produced in a high proportion of breast tumours and is a
favourable indicator of prognosis (Black and Diamandis, 
2000). 
Our objective is to identify genes that may have the potential to
be used as cancer markers. PART-1 (prostate androgen regulated
transcript 1) is predominately expressed in the prostate and is tran-
scriptionally-regulated by androgens in human prostate cancer
cells (Lin et al, 2000). In this report we characterize PART-1 tissue
expression and hormonal regulation by qualitative and quantitative
RT-PCR and found that this gene is frequently up-regulated in
prostate cancer tissues. 
MATERIALS AND METHODS 
Tissue expression 
Total RNA isolated from 27 different human tissues was
purchased from Clontech, Palo Alto, CA. Tissue cDNA was
prepared and PCR amplified at various dilutions with three
different sets of primers (Table 1). One primer set amplified PART-
1, another the PSA transcript and the third set amplified the actin
transcript (the last 2 transcripts served as controls). 
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http://www.bjcancer.comProstate cancer cell line and hormonal stimulation
procedures 
The prostate cancer cell line LNCaP was purchased from the
American Type Culture Collection (ATCC), Rockville, MD. Cells
were cultured in RPMI media (Life Technologies, Inc.) and
supplemented with glutamine (200 mmol l–1), bovine insulin 
(10 mg l–1), fetal bovine serum (10%), antibiotics and antimycotics
in plastic flasks, to near confluency. The cells were then aliquoted
into 24-well tissue culture plates and cultured to 50% confluency.
24 h prior to each procedure, the culture media were changed into
phenol red-free media containing 10% charcoal-stripped fetal
bovine serum. For stimulation, various steroid hormones dissolved
in 100% ethanol were added into the culture media, at a final
concentration of 10–8 M. Cells stimulated with 100% ethanol were
included as controls. The cells were grown for 24 h, after which
they were harvested and total RNA extracted (see below). 
Reverse transcriptase polymerase chain reaction 
Using Trizol™ reagent (Life Technologies, Inc) and following the
manufacturer’s instructions, we extracted total RNA from the cell
line LNCaP. Through spectrophotometry, RNA concentrations
were determined. Using the Superscript™ preamplification
system (Life Technologies, Inc), 2 mg of total RNA was reverse-
transcribed into first strand DNA. The gene-specific primers
(Table 1) were designed through information on the genomic and
cDNA structure of PART-1, obtained from NCBI. PCR reactions
were carried out in a reaction mixture, containing 1 ml of cDNA,
1.5 mM MgCl2, 2.5 ml of 25 mM PCR buffer, 0.5 ml of 10 mM
dNTPs (deoxynucleoside triphosphates), 0.5 ml (150 ng) of
primers, 20 ml of H2O and 0.25 ml (1 unit) of HotStar Taq poly-
merase (Qiagen, Valencia, CA) on an Eppendorf Mastercycler
gradient system (Eppendorf, Westbury, NY). The cycling condi-
tions were 95°C for 15 minutes to activate the HotStar Taq poly-
merase, followed by 35 cycles of 94°C for 30 s, 62°C for 1 minute
and a final extension at 72 °C for 10 minutes. 
Quantitative PCR was performed on a Roche LightCycler®
system (Roche Molecular Biochemicals, Mannheim, Germany).
PCR reactions were carried out in a reaction mixture consisting of
15.2 ml of H2O, 2 mM MgCl2, 0.5 ml (150 ng) of primers, 1 ml of
cDNA and 2 ml of LightCycler DNA Master SYBR® Green I
(Roche). Protocol conditions consisted of denaturation at 95°C for
10 minutes, followed by 40 cycles of 63°C for 55 s and 72°C for 
40 s of extension and data acquisition, with a subsequent melting
at 95°C for 1 s. Quantitative data analysis was made possible,
through the use of PART-1 RNA from serially diluted prostate
cDNA, using 1, 10, 100 and 1000-fold dilutions. These 4 samples
provided the template on which a line of best fit was plotted and
used as a standard curve for data interpretation after each run.
Construction of standard curves and the tabulation of second
derivative peaks displayed the beginning and end of the log-linear
phase of PCR products. 
The amplified PCR products were also separated using 1.5%
agarose gels. The isolated bands were then purified using the
Qiagen gel purification kit. The PCR products were cloned into the
pCR 2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) in order
to verify their identity by sequencing. The inserts were sequenced
in both directions using vector-specific primers with an automated
DNA sequencer. 
Screening for PART-1 transcripts in prostatic tissues 
Included in this study were tissue samples from 27 patients with
prostatic cancer, that had been surgically removed by radical
retropubic prostatectomy. Patient age ranged from 50–68 years,
with a median of 64. Cancerous and non-cancerous pieces of the
whole prostates were carefully excised and verified by histopatho-
logical examination. All patients had a histologically confirmed
diagnosis of primary cancer and received no treatment before
surgery (except patient 1080, who was treated with antihormonal
therapy 4 weeks prior to surgery). 
All tissue samples were minced with a scalpel, on ice and imme-
diately transferred into a 2 ml polypropylene tube. Tissue samples
were then homogenized and RNA extracted using Trizol™ reagent
(Life Technologies, Inc) following the manufacturer’s recommen-
dations. The RNA concentration was determined spectrophoto-
metrically and 2 mg of total RNA was reverse-transcribed into first
strand cDNA as described above. 
RESULTS 
Tissue expression of the PART-1 gene 
As shown in Figure 1, the PART-1 gene is highly expressed in the
prostate, placenta, thymus, and salivary gland, and at lower levels
in trachea, kidney and brain. The PCR-products were subsequently
sequenced to verify the RT-PCR specificity. 
Hormonal regulation of the PART-1 gene 
To verify whether the PART-1 gene is under steroid hormone regu-
lation, the prostate carcinoma cell line LNCaP was used. PSA,
which is up-regulated by androgens and progestins, was used as a
control gene. Our results show that PART-1 is up-regulated by
dihydrotestosterone (DHT) and to a lower extent by oestradiol,
norgestrel (a synthetic progestin) aldosterone and dexamethasone
(Figure 2). 
Malignant versus non-malignant prostatic tissues 
To determine the differential expression levels of PART-1 in
normal (benign) and malignant (cancer) tissues, we analysed 27
pairs of prostatic tissue extracts (normal/cancer) through qualita-
tive and quantitative PCR. We determined that 18 out of 27
patients had elevated PART-1 in the cancerous tissue, 7 had
decreased PART-1 levels in the cancerous tissue compared to the
non-cancerous tissue, while two patients had similar levels in both
(Table 2). The differential expression of PART-1 between normal
and tumour tissues was 93%, with 67% (18 out of 27) of the
matched prostate samples displaying tumour-associated over
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Table 1 Primers used for reverse RT-PCR analysis 
Gene Primer name Sequence 
PART-1 F1 AAGGCCGTGTCAGAACTCAA 
R1 GTTTTCCATCTCAGCCTGGA 
PSA PSAS TGCGCAAGTTCACCCTCA 
PSAAS CCCTCTCCTTACTTCATCC 
Actin ACTINS ACAATGAGCTGCGTGTGGCT 
ACTINAS TCTCCTTAATGTCACGCACGA 
All nucleotide sequences are given in the 5¢ to 3¢ orientation. expression of PART-1. The distribution of quantitative data in the
cancerous and non-cancerous tissues is displayed in Figure 3. The
ratio of PART-1 versus actin was used to normalize the data. 
The difference between PART-1/actin levels in cancerous versus
non-cancerous tissues ranged from approximately 0.03 to 0.24. 
Our quantitative results were further correlated with qualitative
data which were generated by running the amplified samples on
gels. For 20 out of the 27 pairs (74%) the data were concordant by
both methods (Figure 4). The discordant samples included those
with relatively small differences in PART-1 transcripts between
cancer and normal tissues. 
DISCUSSION 
Through the use of a cDNA microarray-based approach (Lin et al,
2000), were able to identify PART-1 and characterize it as an
androgen-induced gene in prostate adenocarcinoma cells, with an
expression restricted to the prostate and salivary glands. They
further demonstrated that the cDNA sequence of PART-1 encodes
for a 60-amino acid protein (Lin et al, 2000). 
Our study extends the data related to PART-1 expression and
regulation. By using a more sensitive detection system, RT-PCR,
rather than the Northern blot analysis used by Lin et al, we were
able to detect and verify that PART-1 is also highly expressed in
the placenta and thymus and to a lower extent in other tissues.
PART-1 is regulated, in prostate carcinoma cells, by a variety of
hormones, although primarily by androgens. It is possible that the
up-regulation of PART-1 by hormones other than androgens may
by due to cross talk between these hormones and the mutant
androgen receptor of LNCaP cells (Veldscholte et al, 1992;
McDonald et al, 2000). This mutant androgen receptor loses its
binding specificity to androgens. 
The finding that PART-1 is frequently present at higher levels in
malignant than in benign tissue, suggests that PART-1 expression is
PART-1 expression in prostate cancer  395
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Figure 1 Tissue expression of the PART-1 gene as determined by RT-PCR.
PART-1 is highly expressed in prostate, placenta, thymus and salivary gland
and to a lower extent in the trachea, kidney and brain and other tissues 
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Figure 2 Hormonal regulation of PART-1 gene in the LNCaP prostate
carcinoma cell line. PSA, acting as a control gene is mainly up-regulated by
dihydrotestosterone (DHT) and by the synthetic androgenic progestin
norgestrel. PART-1 is mainly up-regulated by DHT, but also by oestradiol,
norgestrel, aldosterone and dexamethasone 
C
C
N
N
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
C
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
1119
1080
1137
1136
1128
1120
905
870
863
708
697
689
667
638
598
573
554
548
506
496
464
443
423
422
403
381
357
0
.
0
0
1
0
.
0
0
5
0
.
0
1
0
.
0
5
0
.
1
0
.
5
1
.
0
PART-1/Actin
P
a
t
i
e
n
t
 
I
D
#
Figure 3 Distribution of paired values for the expression of PART-1 in
noncancerous (N) and cancerous(C) prostatic tissues for the 27 patients. The
signal is expressed as a normalized ratio between PART-1 and actin gene.
18/27 patients demonstrate PART-1 upregulation in the cancerous tissue altered during cancer and that its regulation follows different mech-
anisms than PSA, which is usually found in higher levels in benign
tissue (Magklara et al, 2000). The data with PSA, which were
derived by using tissue extracts from the same patients, further
confirm that PART-1 overexpression is not due to higher levels of
luminal epithelium in the cancerous tissues, since PSA is also
produced by prostatic luminal epithelium. PART-1 may be a
secreted protein and its overexpression in cancer lead us to hypoth-
esize that PART-1 may have value as an additional circulating
biomarker for prostate cancer. This possibility merits investigation. 
PART-1 is localized to human chromosome 5q12 and encodes
for a 60-amino acid protein (Lin et al, 2000). The small size of this
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Table 2 RT-PCR analysis of PART-1 transcripts with quantitation by LightCycler technology and by qualitative gel electrophoresis 
Case# Tissue type Patient age PART-1*  Actin* PART-1/Actin Change in Cancer vs. Normal **
Quantitative PCR Qualitative PCR 
357 Normal (N) 65 494 21200 0.023 
Cancer (C) 461 11840 0.038 UP  UP 
381 N 61 273 275200 0.001 
C 1937 25970 0.074 UP UP 
403 N 58 1483 62440 0.023 
C 148 128000 0.001 DOWN DOWN 
422 N 66 797 113000 0.007 
C 4626 28140 0.164 UP UP 
423 N 54 109 29100 0.003 
C 167 41450 0.004 EQUAL EQUAL 
443 N 66 807 60900 0.013 
C 2812 28540 0.098 UP EQUAL 
464 N 64 1391 42760 0.032 
C 579 14300 0.040 UP DOWN 
496 N 65 180 88670 0.002 
C 851 22800 0.037 UP UP 
506 N 67 59 219 0.272 
C 679 2823 0.240 EQUAL UP 
548 N 61 38 5692 0.006 
C 455 6346 0.071 UP UP 
554 N 71 602 11070 0.054 
C 7459 12800 0.066 UP UP 
573 N 50 326 89090 0.003 
C 2329 69120 0.033 UP UP 
598 N 65 647 76920 0.008 
C 1231 5033 0.244 UP UP 
638 N 62 79 121300 0.001 
C 198 42700 0.004 UP EQUAL 
667 N 67 773 16020 0.048 
C 747 36850 0.020 DOWN EQUAL 
689 N 63 1156 14740 0.078 
C 1040 19920 0.052 DOWN UP 
697 N 68 90 1116 0.080 
C 140 4054 0.034 DOWN UP 
708 N 68 844 9240 0.091 
C 2074 11900 0.174 UP UP 
863 N 59 1003 11750 0.085 
C 62 352 0.177 UP EQUAL 
870 N 63 740 35590 0.020 
C 782 28530 0.027 UP UP 
905 N 66 476 24110 0.019 
C 2443 4045 0.603 UP UP 
1120 N 58 903 12430 0.072 
C 1237 4155 0.297 UP UP 
1128 N 68 202 192 1.054 
C 426 2804 0.152 DOWN UP 
1136 N 62 123 15860 0.007 
C 665 12240 0.054 UP EQUAL 
1137 N 69 49 2629 0.018 
C 442 2547 0.173 UP UP 
1080 N 65 448 38120 0.011 
C 67 38590 0.001 DOWN UP 
1119 N 63 193 36970 0.005 
C 26 21940 0.001 DOWN UP 
* Arbitrary units. **UP = increase in PART-1 expression compared to normal tissue; DOWN = decrease in PART-1 expression
compared to normal tissue; EQUAL = equal PART-1 expression in both tissue. polypeptide, along with its hormonal regulation and its restricted
tissue expression pattern, indicates that PART-1 has characteristics
reminiscent of a hormone or a growth factor. Isolation of the
protein and detailed functional and homology analysis should
further illuminate PART-1’s function. 
In conclusion, our finding of overexpression of PART-1 in a
significant percentage of prostate cancers, provides a foundation
for future studies examining the potential of PART-1 as a prostate
cancer marker and its biological function in the prostate and other
tissues. 
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Figure 4 Selected paired samples of normal (N) and cancerous (C) tissues amplified for PART-1 gene expression. Patients 381, 422, and 496 display an
increase in PART-1 expression in the cancerous tissue (see also Figure 3 for quantitative data). Patient 403 has more PART-1 transcript in the normal tissue
while patient 423 depicts equal PART-1 expression in both tissues 